Human immunodeficiency virus (HIV) dementia, also
encephalitides (e.g., herpes simplex virus 1 and 2, JC virus, and cytomegalovirus infections). The latter neuroinvasive vitermed the HIV-1-associated cognitive-motor complex, is a devastating and usually late complication of viral infection.
ruses are tropic for neurons, glia, or both. Importantly, in HIV dementia, both astrocytic and macrophage reactions are associThe clinical syndrome affects 20% of adults and 50% of children with AIDS [1] . Signs of disease begin with subtle ated with brain immune activation initiated by macrophages cognitive changes and physical slowing, progressing to florid and microglia [11] . Activated HIV-1-infected brain macromemory loss, behavioral abnormalities, incontinence, halluciphages secrete a number of factors, many of which are associnations, seizures, and ultimately death [2] [3] [4] [5] . Patients affected ated with neuronal injury [13] . These include but are not limited with severe forms of HIV dementia often have multinucleated to tumor necrosis factor (TNF)-a, platelet activating factor, giant cell encephalitis [5] . The neuropathologic hallmarks of eicosanoids, and nitric and quinolinic acids [14] [15] [16] [17] [18] [19] [20] [21] [22] . Such mac-HIV-1 encephalitis include accumulation or activation of astrorophage secretory products can also cause leakiness of the cytes (astrocytosis) and macrophages (microglial nodules, mulblood-brain barrier, permitting the transendothelial migration tinucleated giant cells) in subcortical white and gray matter.
of monocytes into the central nervous system (CNS) and perNeuronal injury and death often accompany the high levels of petuation of disease. HIV replication seen in the brain during advanced immunosupIf the neuropathologic changes of HIV encephalitis are pression [6] [7] [8] . While most persons with HIV dementia and caused by inflammatory factors released by immune-activated advanced immunosuppression have high levels of virus in the macrophages, it would follow that treatment with antiinflambrain [4] , the converse is not always true [4, [9] [10] [11] . This sugmatory or immunosuppressive agents might positively affect gests that both viral and cellular factors are involved in disease virus-associated CNS pathology. To test this hypothesis, we pathogenesis. used a murine model of HIV encephalitis in which virus-inMacrophages are the major reservoir for HIV-1 in brain fected human monocytes were inoculated into the brains of tissue [6, 12] . This differentiates HIV-1 encephalitis from other severe combined immunodeficient (SCID) mice [23] . Such monocyte inoculation into the brain is accompanied by microglial nodule formation, astrocytosis, and neuronal dropout. These changes persist up to 5 weeks and parallel what is seen in ously following intracerebral macrophage inoculation. Isolation and culture of primary human monocytes. MonoUninfected monocytes 2 (2) 7 (6) 2 (2) 2 (2) 5 (4) cytes obtained by leukapheresis of HIV-1-and hepatitis B-seroUninfected monocytes / negative donors were purified by counter current centrifugal elutridexamethasone 2 (2) 7 (6) 2 (2) 2 (2) 5 (4) ation [24] . Cell suspensions were documented as ú98% monocytes HIV-1 infection of monocytes. After 7 days in Teflon flask suspension culture, monocytes were infected with HIV-1 ADA at an MOI of 0.1 infectious virus per target cell [24] . Culture medium was changed every 3 days. Reverse transcriptase (RT) activity was 1 10 7 cells/mL in serum-free DMEM) was prepared for injections. Anesthetized mice were placed in a stereotaxic apparatus determined in triplicate samples of culture fluids added to a reaction mixture of 0.05% Nonidet P-40 (Sigma), 10 mg/mL poly(A), (Stoetling, Wood Dale, IL) designed specifically for mice. The animal's head was secured by ear bars and mouthpiece as pre-0.25 mg/mL oligo(dt) (Pharmacia Fine Chemicals, Piscataway, NJ), 5 mM dithiothreitol (Pharmacia), 150 mM KCl, 15 mM viously described [26] . The coordinates for inoculation (putamen), confirmed by control india ink injections, were 3.5 mm behind the MgCl 2 , and [ 3 H]dTTP (2 Ci/mmol; Amersham, Arlington Heights, IL) in TRIS-HCl buffer (pH 7.9) for 24 h at 37ЊC. Radiolabeled bregma, 3.5 mm lateral from the sagittal midline at a depth of 4.0 mm and 35Њ from the vertical line. For cell injections, we used a nucleotides were precipitated with cold 10% trichloroacetic acid and 95% ethanol in an automatic cell harvester (Skatron, Sterling, 100-mL Hamilton syringe and a 26-gauge needle. Each animal brain received 15 mL of suspension containing 3.0 1 10 5 HIV-VA) on paper filters. Radioactivity was estimated by liquid scintillation spectroscopy [25] . The percentage of HIV-infected monoinfected or uninfected cells. Animals were sacrificed from 4 days to 4 weeks after inoculation. Similar numbers of human monocytes cytes was determined by immunostaining with anti-HIV-1 p24 monoclonal antibody (MAb; Dako, Carpinteria, CA). Cytospin were identified in HIV-1-infected and control uninfected monocyte-inoculated animals in each of the three independent experipreparations of HIV-1-infected or noninfected cells were fixed in cold absolute acetone/methanol (1:1) for 10 min at 020ЊC; antiments by morphologic and immunohistochemical analyses. Dexamethasone administration. Animals were inoculated with p24 MAb (1:10; Dako) was applied for 60 min at room temperature, followed by treatment with a fluorescein isothiocyanate HIV-1-infected and control uninfected monocytes as described above. At 24 h before intracerebral injection of the monocytes, (FITC)-conjugated anti-mouse IgG F(ab) 2 fragment (1:100; Boehringer Mannheim, Indianapolis) for 1 h at room temperature.
Days after monocyte inoculation

Material s and Methods
half of the mice (treated group) were injected subcutaneously with dexamethasone acetate (Schein Pharmaceutical, Florham Park, Viral antigen-positive cells were counted microscopically (Microphot-FXA; Nikon, Tokyo) using a 120 objective in 10 random NJ). A repository form of the drug was used, with an average duration of action of 7-9 days. Mice were given dexamethasone fields and an FITC filter. All experiments were done in triplicate.
Animals and intracerebral injections in the SCID mouse model. (14 mg/kg/week) until sacrifice. Mice from each treatment arm were sacrificed at 4, 7, 14, 21, and 28 days after injection. Control SCID mice (male C.B-17/IcrCrl-SCID-bgBR, 3-4 weeks old) were purchased from Charles River Laboratories (Wilmington, mice were treated with dexamethasone or left untreated, injected with media alone (sham), and sacrificed 1 and 4 weeks after injec-MA). Animals were maintained in sterile microisolator cages under pathogen-free conditions in the Laboratory of Animal Medicine, tion. Three additional control mice received no intracerebral injections but were treated with dexamethasone at equivalent dosages University of Nebraska Medical Center. All animal manipulations (including intracranial inoculations) were done in a laminar flow and sacrificed at weeks 1, 3, and 4. Immunohistochemistry was done on 5-mm paraformaldehyde-NEL reaction mixture was used as a negative control. Pretreatment of slides with DNase (10 min at room temperature) to induce DNA fixed paraffin-embedded or cryostat sections fixed in absolute acetone/methanol (1:1) for 10 min at 020ЊC. Human monocytes were strand breaks served as a positive control. Normal human tonsil and small intestine tissues were used as additional controls for identified immunocytochemically with anti-CD68 KP-1 (1:100; Dako) or anti-vimentin (1:25; Boehringer Mannheim) MAbs. Huthe TUNEL assay; both tissues have a high cell turnover and concomitant apoptosis under normal physiologic conditions. man TNF-a, interleukin (IL)-1b, and IL-6 were detected with polyclonal rabbit anti-human TNF-a, IL-1b, and IL-6 antibodies
Reversed-phase high-performance liquid chromatography (RP-HPLC). Arachidonic acid metabolites (AAMs) and unla-(Genzyme, Cambridge, MA) at a dilution of 1:25. Mouse endothelial cells or astrocytes were recognized with polyclonal antibodies beled arachidonic acid (AA) were purchased (Sigma) as were [5, 6, 8, 9, 11, 12, 14, Indirect immunofluorescence detection (secondary antibodies) nosa serotype 10 and zymosan A obtained from Saccharomyces cerevisiae were purchased (Sigma). Opsonized zymosan (OpZ) was done with FITC-coupled anti-mouse IgG F(ab) 2 and antirabbit IgG antibody F(ab) 2 (Boehringer Mannheim; 1:100 diluwas prepared by boiling 0.05 g of zymosan in 36 mL of PBS for 1 h, centrifuging at 1200 g for 8 min, and washing with PBS. The tion) labeled with rhodamine or goat anti-rat antibody F(ab) 2 fragment (Biosource), coupled with FITC. Immunostained tissues were zymosan was then incubated for 30 min with 20% freshly prepared human serum, washed twice with PBS, and stored at 070ЊC. analyzed microscopically (Microphot-FXA; Nikon). Double labeling (with anti-CD68 and anti-GFAP) was done on replicate tissue
For detection of AAMs in immune-stimulated monocytes, cells (3.6 1 10 6 /well) were cultured in Primaria 9.6-cm 2 wells (Fisher, sections to characterize astrocyte and human monocyte reactions. Deletion of the primary antibody or use of mouse IgG or rabbit Pittsburgh) in DMEM containing M-CSF. HIV infection of cells was done as described above. AAMs were analyzed on days 5, IgG (Dako) served as controls. To detect antigens (CD68, HLA-DR, HIV-1 p24, GFAP, vimentin, neuronal-specific enolase, MAP-10, and 14 after viral infection. Briefly, 10 mCi of [ 3 H]AA was added to each well for 18 h. Dexamethasone (EtOH soluble; 2, neurofilaments, and PGP 9.5) on paraffin sections, avidin-biotin immunoperoxidase staining (Vectastain Elite ABC kit; Vector LabSigma) was then added to cultures of HIV-1-infected and control uninfected cells at 10 04 M 45 min before stimulation with LPS oratories, Burlingame, CA) was used with 3,3-diaminobenzidine as the chromogen. All sections were counterstained with Mayer's (10 mg/mL) or OpZ (300 mg/mL). The reaction was stopped 2 h after stimulation by addition of 10 mL of formic acid, 25 mL of hematoxylin.
In situ detection of apoptotic cells. Labeling of cells for butylated hydroxytoluene (10 mg/mL), and 0.6 mL of methanol. The plates were quickly frozen in a dry ice-ethanol mixture and apoptosis (programmed cell death) was done on paraffin sections using an in situ cell death detection kit (Boehringer Mannheim). stored at 070ЊC. Cells were thawed, the lysate-culture supernatant (figure 1). At autopsy, dexamethasone-treated mice had atrophy (1.3 mCi/mL) in known concentrations, was added to the clarified of the adrenal cortex ( figure 1A, B) . The weight differences supernatant, and the samples were placed under argon at 020ЊC.
between treated and untreated groups of mice were statistically
The pH of each 3-mL sample was adjusted to 4.0 with 9.0 mL of significant (P õ .002; figure 1C ). There were no weight differacidified water (1 mL of 22 M formic acid/1 mL of dH 2 O).
A cartridge (C18 Sep-Pak; Waters) was activated by adding 6
ences between groups injected with uninfected or HIV-1-inmL of HPLC-grade methanol to the cartridge and washing with 7 fected monocytes (data not shown). lyzed. As observed in our previous studies, the inflammatory
The AAMs were dissolved in 1 mL of methanol, vortexed, freezecomponent of HIV encephalitis in the mouse brains was greatdried, resuspended in 100 mL of methanol, transferred to 0.8-est 7 days after injection. There was negligible needle tract- increased GFAP immunostaining) was in proportion to the quent RT analysis (described previously). TNF bioassays followed number of human monocytes detected. Dexamethasone treatstandard laboratory procedures [15, 27] . Viability of macrophages ment had no effect on the number or distribution of the monowas assessed on days 7 and 14 after infection by conversion of cytes identified in the sections (figure 2b). Human monocytes MTT bromide. Color intensity was measured at 490 nm [28, 29] .
were found in 6 of 7 dexamethasone-treated animals. HLA- (figure 2f, h) were not affected by dexamethasone treatment. In addition, GFAP content was not affected by glucocorticoid Results treatment in the contralateral (noninjected) hemispheres in places of usual astrocyte accumulation (corpus callosum, interThe neuropathogenesis of HIV-1 encephalitis remains poorly understood, and there are few therapeutic options. Much current nal and external capsules and walls of ventricles, brainstem, and major fiber tracks; data not shown). research in HIV dementia is directed toward understanding how secretions from immune-activated HIV-1-infected macroMorphologic analysis of sham-inoculated mice demonstrated a very focal and minimal astrocytic response along the needle phages produce the pathologic changes, including the hallmark neuronal loss. Because corticosteroids are broad-acting potent track in basal ganglia and cortex 1 week after animal manipulation. Sham-inoculated dexamethasone-treated mice showed enantiinflammatory drugs, they were our initial choice for therapeutic development for HIV dementia. A long-acting (reposihanced GFAP immunostaining of astrocytes that was not restricted to the needle track. Moderately hypertrophied tory) form of dexamethasone acetate was chosen to decrease handling stress of the mice.
astrocytes were found in basal ganglia and around ventricles treated) are on the left and dexamethasone-treated mice are on the right. HIV-1-infected cells were seen in 6 of 7 control (untreated) animals (12-160/section, mean 62; figure 3a) and were distributed similarly to the uninfected cells. In total, 37% of monocytes immunostained with HIV-1 p24, 80% expressed HLA-DR (figure 3e), and many multinucleated giant cells were demonstrated (figure 3c). A notable astrogliosis again was seen around the injection site but was more widespread (800 mm) and intense than observed with uninfected cells. As previously shown, dexamethasone treatment did not affect the mean number or distribution of monocytes (figure 3b; monocytes were found in 6/7 dexamethasone-treated animals), p24 antigen expression, giant cell formation (figure 3d), or HLA-DR expression (figure 3f). The intensity or distribution of astrogliosis in the injected hemisphere was either not affected or was slightly increased following treatment (figure 3h, j). Dexamethasone had no effect on astrocyte responses in the contralateral (noninjected) hemisphere (data not shown).
We next evaluated the effect of dexamethasone treatment on neuronal injury. Figure 4 illustrates brain pathology of mice injected with uninfected monocytes with controls (untreated) on the left and dexamethasone-treated mice on the right. Figure  4 (a, b) shows the injected human monocytes in the area of analysis. Shrunken neurons with hyperchromic nuclei were in and around the injection site. Cells containing nuclei with condensed chromatin were occasionally found around uninfected monocytes in the cortex and putamen. The TUNEL technique showed neural cells undergoing programmed cell death (detected by DNA fragmentation). Apoptosis was minimal in mice injected with uninfected monocytes (detected in 1/7) and was not observed in the contralateral hemisphere (figure 4c, e, respectively). Few cells smaller than neurons (of unidentified origin) had clear evidence of apoptosis. Cortical neurons showed increased aggregation of neurofilaments in cell bodies, while the neurofilament content in axons was decreased (figure 4g). The contralateral (noninjected) hemispheres showed normal distribution of neurofilament (figure 4i). These changes were accompanied by a modest local vacuolation of neuronal processes around human cells. Dexamethasone treatment caused modest increases in the level of apoptosis (detected left and dexamethasone-treated animals on the right). Figure 5 (a, b) shows a representative distribution of numbers of monoand a more diffuse reaction compared with media-inoculated treated mice. Few shrunken neurons were located near the cytes in affected brain areas. Many neurons undergoing programmed cell death were detected by apoptotic staining in 5 needle track in sham-inoculated animals (data not shown). , 1200 (a, b, g, h) ; 1400 (c, d); 140 (e, f).
neurofilament aggregation and axonal damage were more prowas detected in 6 of 7 animals, and changes were more widespread than in untreated HIV-1-infected monocyte-inoculated nounced than with uninfected cells (figure 5g), and no changes were found in the contralateral hemisphere (figure 5i). With animals (figure 5d). Such neuronal changes were absent in the contralateral hemispheres (figure 5f). Dexamethasone treatment dexamethasone treatment, programmed cell death of neurons untreated (a, c, e, g, i) and treated (b, d, f, h, j) mice immunostained with antibodies to CD68 (a, b), neurofilament (g-j), or labeled for apoptosis by transferase-mediated dUTP nick end-labeling method (e-f). Tissue sections (a, b, g-j) were counterstained with Mayer's hematoxylin. Original magnifications, 1200 (a, b) ; 1100 (c-j). had no effect on neurofilament redistribution (figure 5H) or on neurofilament immunostaining in the contralateral hemisphere (figure 5j).
The effect of dexamethasone on the microglial nodule formation was next investigated. As found in our previous studies, F4/80-positive microglia formed aggregates around human monocytes 4 days after injection and peaked 7-12 days after monocyte inoculation. The degree of microglial accumulation and signs of cellular activation were dependent upon the number of HIV-1-infected monocytes. Mice injected with uninfected monocytes showed minimal microglial accumulation, which was unaffected by dexamethasone treatment (data not shown). Figure 6 shows mice injected with HIV-infected monocytes (untreated controls, left; dexamethasone-treated on right). Control mice showed focal aggregation of microglia (figure 6a) around HIV-infected monocytes (figure 6c); contralateral hemispheres showed no signs of cellular (microglial) activation (figure 6e). Dexamethasone-treatment resulted in increased microglial accumulation and activation. These microglial reactions were more diffuse with less distinct nodule formation (figure 6b); no effect on microglial formation was observed in the noninjected hemisphere (figure 6f).
Vascular cell adhesion molecule-1 (more pronounced on microvessels in hemispheres receiving HIV-1-infected monocytes) and ICAM-1 expression (more obvious in mouse brains inoculated with control cells) were down-regulated in mice treated with dexamethasone. VLA-4 expression on microglia and mouse macrophages was unaffected by glucocorticoids (data not shown).
Taken together, the results obtained in this study confirm that injection of HIV-1-infected monocytes into the brains of SCID mice result in increased levels of astrocytosis, microglial hance vulnerability of brain tissue to other (nonviral) types of harmful insults.
Effect of dexamethasone on TNF and prostaglandin E 2 h after LPS stimulation. Dexamethasone decreased TNF secretion to õ80% of that in control (untreated) cells. Maximal (PGE 2 ) secretion from human macrophages. Because of the effect of dexamethasone on the neuropathology of our SCID effects were seen only at the highest concentration, 10 04 M, whereas at 10 06 M, only a small (Ç20%) decrease in the TNF mouse model of HIV encephalitis, we evaluated possible mechanisms for these observations. TNF is one of many macrophage level was observed. Given the volume of distribution of dexamethasone in the mice, the highest molar concentrations secretory products thought to contribute to the neuropathology of HIV encephalitis. To evaluate the effect of dexamethasone achievable in animals is projected to be 10 06 -10 04 M. A number of AAMs are thought to play a role in the neuronal on TNF secretion, both uninfected and HIV-1-infected monocytes were treated with dexamethasone in increasing concentradamage of HIV-1 encephalitis. To evaluate the effect of dexamethasone on AA metabolism, HIV-1-infected and control tions prior to stimulation with LPS. Samples were collected 4-24 h after stimulation and analyzed for TNF bioactivity.
uninfected macrophages were treated in vitro with dexamethasone (10 04 M) before stimulation by OpZ. After cells and super- Figure 7 shows TNF production for HIV-1-infected cells 12 Figure 8 . Prostaglandin E 2 (PGE 2 ) production in monocytes after (0.1 infectious virus particle/cell) and cultivated 7 days. Cells were opsonized zymosan (OpZ) activation and dexamethasone treatment. treated with 10 mg/mL LPS with and without dexamethasone. Results
Monocytes were inoculated with HIV-1 ADA (0. natants were collected and extracted, PGE 2 production was measured by RP-HPLC. The results (figure 8) demonstrate a trend toward decreased PGE 2 production by HIV-1-infected macrophages in the presence of the highest doses of dexamethasone, but again, suppression was incomplete.
Effect of dexamethasone on HIV replication. If dexamethasone caused an increase in HIV replication, this might account for the therapeutic failure of dexamethasone in our mouse model. Indeed, the concern for increased viral replication in the presence of corticosteroids has tempered the use of such drugs during progressive HIV disease for problems such as idiopathic thrombocytopenic purpura. A recent study, however, suggests this may not be biologically relevant. In that study, AIDS patients treated with systemic steroids had improved CD4 / T cell counts [34] . To evaluate the possibility that dexamethasone could alter HIV-1 replication in monocytes and thereby modulate virus-induced neurotoxicity, we treated cell cultures (both HIV-1-infected and uninfected) with dexamethasone at 10 04 and 10 06 M. Samples were collected every other day and analyzed for RT activity. Dexamethasone treatment decreased RT activity compared with that of untreated HIV- leading to absolute increases in monocytes in the brain. To asone to affect pathology in our model of HIV-1 encephalitis supports the notion that specific viral factors play a role in disease pathogenesis. Our in vitro studies showed that although dexamethasone could induce a modest decrease in TNF and PGE 2 production from HIV-1-infected monocytes, an increase in cell viability of the infected monocyte likely negated any concomitant decrease in neurotoxic secretions. These results are in agreement with previously published works. In Borna disease-induced encephalitis, dexamethasone treatment did not down-regulate TNF-a, IL-6, macrophage inflammatory protein-1b, and mob-1 in the CNS of rats [35] . These findings, in total, suggest a refractoriness of resident brain macrophages and microglia to corticosteroid treatments. The down-regulation of TNF and PGE 2 by dexamethasone in our model may not indicate that these molecules do not play a role in disease. Low-level production of TNF and PGE 2 may be necessary, but not sufficient, broadly acting antiinflammatory drug, it is difficult to specify activity 7 days after infection. the exact roles played by TNF and PGE 2 in disease pathogenesis. Nevertheless, the reduction of both of these factors failed to affect the neuropathologic outcomes for disease. This sugevaluate this issue, cultured monocytes (HIV-infected and ungests, at the least, that multiple factors are involved in the infected) were treated with dexamethasone (two different prepneurotoxicity observed during CNS HIV-1 infection. arations) at 10 04 and 10 06 M. Viability was measured by MTT An additional possibility for the therapeutic failure of dexaconversion assays 7 and 14 days after infection. Dexamethamethasone in this model revolves around the complex and sone increased viability in HIV-1-infected cells compared with diverse actions of glucocorticoids in the brain. As reviewed by controls (untreated cells; figure 10). These differences were Sapolsky [36], glucocorticoids can have deleterious effects on statistically significant (P õ. 001) but were seen only in in-CNS function. Sustained exposure to high levels of glucocortifected cells. Paradoxically, dexamethasone decreased cell viacoids in brain tissue can directly damage or atrophy the hippobility in uninfected monocytes.
campus (assessed as neuronal loss) in various animal species (guinea pigs, rats, mice, and Old World primates) and accelerate hippocampal aging. Hippocampal atrophy, as measured by Discussion magnetic resonance imaging, is often seen in human Cushing's syndrome. In major depression disorders (in which about half We used a SCID mouse model for HIV-1 encephalitis to investigate the therapeutic efficacy of glucocorticoids. Our hyof affected persons are hypercortisolemic), hippocampal atrophy is also present. Glucocorticoids also impair glucose pothesis was based on the idea that HIV-1-infected macrophages or microglia are the main reservoir for virus in brain uptake. This renders neurons more susceptible to injury from excitotoxic and metabolic insults through augmentation of and are the perpetrators for neurotoxic secretions, and that their numbers correlate with the clinical severity of HIV-1 dementia. extracellular excitotoxic amino acid accumulation, free cytosolic calcium, and an exacerbation of calcium-dependent We anticipated that brain pathology (including astrogliosis, microglial nodule formation, and neuronal injury) would dineurodegeneration. Such mechanisms help to explain the findings seen here of worsened HIV-1 -associated neuropaminish after dexamethasone treatment. Even though high levels of drug were achieved, signs of monocyte-induced damage in thology, including increased neuronal apoptosis after dexamethasone treatment. the CNS were in many instances surprisingly exacerbated.
Multiple mechanisms could have been involved in this apThe effects of dexamethasone in worsening needle traumainduced neuropathology indicates that such treatments may parent therapeutic failure. Viral gene products (gp120, tat, nef, and others) are involved in neurotoxic activation of HIV-1-impair the ability of the brain to recover from CNS trauma and perhaps other noxious insults. Others have reported increased infected macrophages [13] . Although dexamethasone decreased HIV-1 replication in cultured monocytes (as measured neuronal apoptosis in the hippocampus in a rabbit model of pneumococcal meningitis following treatment with dexamethaby RT activity), its effect was modest. The failure of dexameth-sone [37] . Alternatively, dexamethasone given in supraphysiotherapies may ultimately prove invaluable to prevent or treat this important complication of HIV-1 infection in humans. logic doses could have produced systemic effects that confounded the results presented in this report. For example, our treated mice showed signs of failure to thrive. Such findings are seen commonly in children given high doses of glucocorticoids,
